Home

Keep The Faith…Rubber Eventually Meets Road

Daniel Carlson -
9
One of my readers has been leaving me a lot of messages about Anixa (ANIX) of late. The general gist of his communication is...
Read more

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at...

Daniel Carlson -
0
TW's Take: INKmune continues to have outstanding data that makes it potentially the market leader in NK cell therapies. The data being presented looks...
Read more

May 22, 2023…Premium Subscriber Update

Daniel Carlson -
3
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

Daniel Carlson -
3
TW's Take: nice to see this program gaining some momentum. Due to changes in their recruitment process, expect to see enrollment accelerate and results...
Read more

Back in the Saddle

Daniel Carlson -
3
Last week I took off from publishing as I was meant to be skiing out west. Well, not exactly skiing in the traditional sense...
Read more

IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

Daniel Carlson -
0
TW's Take: INAB is looking to partner their programs and the strong results in conjunction with TMZ, the standard of care in many cases,...
Read more

Spectra7 Announces 50% Y-o-Y Revenue Growth in First Quarter 2023, Affirms Outlook for Q2...

Daniel Carlson -
0
TW's Take: SPVNF is poised to grow rapidly if they can execute on landing a large piece of the US data center market's upgrade...
Read more

TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to...

Daniel Carlson -
5
TW's Take: nice to see that the technology continues to impress enough to sign a CRADA but we await the real news of phase...
Read more

IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th...

Daniel Carlson -
0
TW's Take: More positive data that pulls in another possible avenue for partnering. Preclinical data demonstrates that gamma-delta T cells have the ability to...
Read more

May 2, 2023…Trading Update

Daniel Carlson -
0
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under...

Daniel Carlson -
0
TW's Take: nice to see that this program continues to advance. TFF has been quiet for a while. Expect to see some more news...
Read more

This Time It’s Different!

Daniel Carlson -
10
My thesis heading into 2023 was to expect a trader's market. This looked to be a year filled with catalyst driven moves and high...
Read more

April 27th, 2023 Trade Update…ATOM and INAB

Daniel Carlson -
1
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Atomera Signs Commercial License Agreement with STMicroelectronics

Daniel Carlson -
1
TW's Take: very exciting news for ATOM as they are closer than ever to getting into production. The finish line is coming into sight...
Read more

April 26, 2023 Trade Update

Daniel Carlson -
5
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to...

Daniel Carlson -
0
TW's Take: obviously good data with an oral presentation, INAB continues to kick butt in all their clinical programs. NEW YORK, (GLOBE NEWSWIRE) -- IN8bio,...
Read more

Spectra7 Announces 107% Revenue Growth for 2022, Pre-announces Q1 2023 and Outlook for Q2...

Daniel Carlson -
0
TW's Take: solid results but it's all about their guidance for data center wins in the 2nd half of 2023. If this comes to...
Read more

IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T...

Daniel Carlson -
0
TW's Take: simply outstanding data from this program. While the balance sheet remains an issue, the value being created here is substantial and we...
Read more

Anixa Delivers On The Data While The Stock Rollercoasters

Daniel Carlson -
3
A few weeks back I wrote about catalysts that weren't going to help your stocks. It was meant to be a little tongue in...
Read more

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease

Daniel Carlson -
0
TW's Take: this trial demonstrates that inhibiting TNF arrests the development of amyloid pathology in TBI patients, but also gives hope that this works...
Read more

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.